Synapse - Neil Segal

Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)

Meeting Abstract

Segal, N. H.; Saro, J.; Melero, I.; Ros, W.; Argiles, G.; Marabelle, A.; Rodriguez Ruiz, M. E.; Albanell, J.; Calvo, E.; Moreno, V.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA-CD3 TCB) for the treatment of CEA-positive solid tumors

Meeting Abstract

Melero, I.; Segal, N. H.; Saro, J.; Ros, W.; Martinez-Garcia, M.; Argiles, G.; Moreno, V.; Ponce, S.; Marabelle, A.; Cleary, J. M.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)

Meeting Abstract

Argilés, G.; Saro, J.; Segal, N. H.; Melero, I.; Ros, W.; Marabelle, A.; Rodriguez, M. E.; Albanell, J.; Calvo, E.; Moreno, V.; more...
Annals of Oncology (2017)

Fulltext@MSK | Save

Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer

Journal Article

Goodman, K. A.; Julie, D.; Cercek, A.; Cambridge, L.; Woo, K. M.; Zhang, Z.; Wu, A. J.; Reidy, D. L.; Segal, N. H.; Stadler, Z. K.; more...
International Journal of Radiation Oncology, Biology, Physics (2017)

Fulltext@MSK | Save

Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

Journal Article

Segal, N. H.; Logan, T. F.; Hodi, F. S.; McDermott, D.; Melero, I.; Hamid, O.; Schmidt, H.; Robert, C.; Chiarion-Sileni, V.; Ascierto, P. A.; more...
Clinical Cancer Research (2017)

Fulltext@MSK | Save

Expression of PD-L1 in colorectal carcinoma (CRC) primarily occurs in stromal/immune cells at tumor-stroma interface (TSI), and is associated with high tumor-infiltrating lymphocytes (TILs) irrespective of the microsatellite instability (MSI) status or the molecular mechanism of MSI

Meeting Abstract

Liu, S.; Hechtman, J.; Segal, N.; Smith, J.; Rao, D.; Markowitz, A.; Weiser, M.; Vakiani, E.; Klimstra, D. S.; Stadler, Z.; more...
Modern Pathology (2017)

Fulltext@MSK | Save

Morphological characterization of colorectal cancers in the Cancer Genome Atlas reveals distinct morphology-molecular associations: Clinical and biological implications

Journal Article

Shia, J.; Schultz, N.; Kuk, D.; Vakiani, E.; Middha, S.; Segal, N. H.; Hechtman, J. F.; Berger, M. F.; Stadler, Z. K.; Weiser, M. R.; more...
Modern Pathology (2017)

Fulltext@MSK | Save

Expression of PD-L1 in colorectal carcinoma (CRC) primarily occurs in stromal/immune cells at tumor-stroma interface (TSI), and is associated with high tumor-infiltrating lymphocytes (TILs) irrespective of the microsatellite instability (MSI) status or the molecular mechanism of MSI